| 2.34 -0.3 (-11.36%) | 12-16 13:46 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Titan Pharmaceuticals, Inc. is a pharmaceutical company dedicated to creating treatments for chronic conditions, with its product development centered around ProNeura, a unique platform designed for extended drug release. Currently, the company markets the Probuphine implant in Canada and the European Union. This implant provides maintenance treatment for clinically stable individuals struggling with opioid use disorder. Beyond Probuphine, Titan Pharmaceuticals is advancing several pipeline candidates. Among these is the kappa opioid agonist peptide program (TP-2021), which utilizes the ProNeura technology to address chronic pruritus. Another key development is a nalmefene implant program, aimed at preventing opioid relapse in patients after detoxification from opioid use disorder. Furthermore, the company is exploring other applications for its ProNeura platform, including a single implant for HIV prevention and a contraceptive option for women and adolescent girls. Established in 1992, Titan Pharmaceuticals operates from its base in South San Francisco, California.
Thu, 09 Oct 2025
ARC Group Advises Black Titan Corporation on Black Titan Corporation’s (NASDAQ: BTTC) - ARC Group
Fri, 03 Oct 2025
Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation - Yahoo Finance
Thu, 24 Apr 2025
Ensysce Biosciences (ENSC) Stock Price, News & Analysis - Stock Titan
Thu, 24 Apr 2025
60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis - Stock Titan
Fri, 06 Dec 2024
Titan Pharmaceuticals appoints new CEO, changes accountant - Investing.com
Thu, 25 Jan 2024
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|